Forecast
Partial artificial gestation is used clinically for premature humans by 2126.
Last revised Sep 11, 2026.
Current estimate
probability this has happened by each date
Approved extra-uterine support replaces a meaningful portion of late gestation for premature human infants.
Resolution criteria
- 2126
- Approved extra-uterine support replaces a meaningful portion of late gestation for premature human infants.
Probability history
| Revised | State | p(2035) | p(2050) | p(2100) |
|---|---|---|---|---|
hf-forecast-0026 | researched | — | — | — |
hf-forecast-0005 | initial prior | — | — | — |
Strongest evidence for
- The FDA's Pediatric Advisory Committee reviewed artificial womb technology on 19 September 2023 and named the prerequisites for a human trial, which converts a laboratory result into a regulated product pathway (hf-evidence-0052).
- Vitara Biomedical, spun out of the group behind the original lamb work, raised 50 million dollars in November 2024, so the pathway has capital behind it (hf-evidence-0052).
- The original pumpless arteriovenous result supported lambs for 25 to 28 days and still stands as a landmark demonstration.
Strongest evidence against
- Only one of six lambs completed the protocol in an independent 2023 replication; three were euthanised after bladder bleeding and two after umbilical artery vasoconstriction (hf-evidence-0049).
- Supported animals showed significantly reduced lung, liver and kidney weights and a humerus growth deficit of 2.9 against 4.8 centimetres versus in-utero controls (hf-evidence-0049).
- IGF-1 was 17 against 140 micrograms per litre, an approximately 88 percent reduction, so the animals were cardiovascularly stable while not growing (hf-evidence-0049).
- FDA-presented piglet data showed heart failure within hours to days, materially worse than the lamb results, and FDA staff concluded the technology is harder at younger gestations and in smaller patients (hf-evidence-0052).
Present uncertainties
- Whether second-generation devices close the growth gap, or whether cardiovascular support without normal somatic growth is the ceiling of the approach.
Next discriminating observation
The first authorised human trial of extra-uterine support; and the first published animal result showing normal organ growth and IGF-1 rather than only stable circulation.
Sources
- Artificial placenta support of extremely preterm ovine fetuses at the border of viability for up to 336 hours
Six lambs at 93 to 94 days gestation, about 600 grams, were supported for a mean of 250 plus or minus 72 hours with a maximum of 336. Only one of six completed the protocol; three were euthanised after bleeding from the bladder and two after umbilical artery vasoconstriction. Against in-utero controls, lung weight was 37.0 versus 45.7 grams, liver 53.0 versus 75.25, kidney 9.5 versus 12.9, and humerus growth 2.9 versus 4.8 centimetres, all statistically significant. IGF-1, a principal fetal growth hormone, was 17 plus or minus 7 micrograms per litre against 140 plus or minus 18 in controls.
Limit: One study, six animals, one species and one device configuration. It does not establish that every artificial placenta approach impairs growth, and first-generation device deficits are the kind of problem engineering usually reduces.
Fetched and confirmed directly by the master agent.
- FDA advisory review and commercial investment in extra-uterine support
The FDA's Pediatric Advisory Committee reviewed artificial womb technology on 19 September 2023 and named prerequisites for a human trial under the paediatric research regulations, including a proposed initial enrolment restricted to very high risk neonates. Vitara Biomedical, spun out of the group behind the original lamb work, raised a 50 million dollar Series B in November 2024. FDA-presented piglet data showed heart failure within hours to days, materially worse than the lamb results, and FDA staff concluded the technology is likely to be more difficult at younger gestations and in smaller patients.
Limit: An advisory committee review is not an approval, no human trial has been authorised, and the piglet results show the outcome depends on species and size rather than on the concept alone.
Retrieved by a delegated source worker and not independently re-fetched.